Treatment of sleep disorders with melatonin

BMJ 2012; 345 doi: http://dx.doi.org/10.1136/bmj.e6968 (Published 5 November 2012)
Cite this as: BMJ 2012;345:e6968

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Alexander Lerchl, professor of biology1,
  2. Russel J Reiter, professor2
  1. 1Jacobs University Bremen, D-28759 Bremen, Germany
  2. 2University of Texas Health Science Center, San Antonio, TX, USA
  1. a.lerchl{at}jacobs-university.de

Children with neurodevelopmental disability sleep better but may wake earlier

Melatonin (N-acetyl-5-methoxytryptamin) is synthesized in the pineal body exclusively during periods of darkness. It plays an important role in initiating and maintaining sleep. In elderly people, concentrations of endogenous melatonin usually decline, and this is often associated with insomnia.1 Treatment with melatonin is effective in restoring normal sleep and improving quality of life in people over 55 years of age.1 Melatonin has also been used to treat children with developmental disabilities and sleep difficulties. It has been shown to be preferable to hypnotics, such as clonidine and benzodiazepines, because it does not affect sleep architecture or have adverse side effects.2 3 4

In a linked research paper (doi:10.1136/bmj.e6664) Gringras and colleagues randomised 146 children with neurodevelopmental delay and other diseases (epilepsy or autistic …

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Article access

Article access for 1 day

Purchase this article for £20 $30 €32*

The PDF version can be downloaded as your personal record

* Prices do not include VAT

THIS WEEK'S POLL